Interviews

Neeraj Agarwal, MD, discusses the efficacy of cabozantinib and atezolizumab in the COSMIC-021 study.

David Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.

Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.

Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.

Thomas Powles, MD, MBBS, MRCP, discusses how researchers are working to optimize treatment with immune checkpoint inhibitors for patients with urothelial carcinoma.

Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.

David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.

David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.

Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.

Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.

Van K. Morris, MD, describes the novel treatments he is excited about in the treatment landscapes for colorectal and anal cancers right now.

Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.

Elizabeth A. Mittendorf, MD, PhD, discusses different data looking at sequencing therapies and why it is important in the breast cancer setting.<br /> &nbsp;

Stephen J. Freedland, MD, discussed&nbsp;an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.

Dylan Essner explains how Epic, an electronic medical record, can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor T-cell therapy.

Lori A. Leslie, MD, discusses chimeric antigen receptor T-cell therapy as a treatment for diffuse large B-cell lymphoma and the positive results demonstrated for this agent in patients with relapsed/refractory disease.

Benjamin P. Levy, MD, discusses the role of biomarkers in the treatment landscape for patients with lung cancer.

David Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.

Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L&nbsp;vaccine in melanoma.

John M. Pagel, MD, PhD, discusses the current setting of diffuse large B-cell lymphoma and some of the treatments available at the moment.

Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with&nbsp;myelofibrosis-associated anemia.

William K. Oh, MD, discusses phase III studies in the prostate cancer setting which led to the use of these new treatments, such as androgen receptor targeted therapies with chemotherapy in earlier disease settings.

Stephen Boorjian, MD, discusses the efficacy results of the phase II study intravesical nadofaragene firadenovec in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer, which he presented at the 2020 Genitourinary Cancer Symposium.&nbsp;

Zofia Piotrowska, MD, MHS, discusses the data from the randomized phase III FLAURA trial, which led to the widespread use of frontline osimertinib for the treatment of&nbsp;EGFR-mutant lung cancers.

Jeff P.&nbsp;Sharman, MD, discusses what differentiates acalabrutinib from other BTK inhibitors available in chronic lymphocytic leukemia.

Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.

Andrew J. Cowan, MD, explains the rationale for a phase I clinical trial in which a gamma-secretase inhibitor was combined with CAR T-cell therapy as treatment for heavily pretreated patients with multiple myeloma.

Karl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.